e-learning
resources
Glasgow 2004
Tuesday 07.09.2004
Epidemiology: miscellaneous including cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease
Y. M. Gagnon, A. H. Briggs, A. R. Levy, S. Spencer, G. Bale, M. D. Spencer, P. S. Burge (Vancouver, Canada; Oxford, London, Birmingham, United Kingdom)
Source:
Annual Congress 2004 - Epidemiology: miscellaneous including cancer
Session:
Epidemiology: miscellaneous including cancer
Session type:
Thematic Poster Session
Number:
3686
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. M. Gagnon, A. H. Briggs, A. R. Levy, S. Spencer, G. Bale, M. D. Spencer, P. S. Burge (Vancouver, Canada; Oxford, London, Birmingham, United Kingdom). Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease. Eur Respir J 2004; 24: Suppl. 48, 3686
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease
Source: Eur Respir J 2004; 23: 241-249
Year: 2004
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 21: 74-81
Year: 2003
Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease
Source: Eur Respir J 2002; 20: Suppl. 38, 241s
Year: 2002
Safety of salmeterol / fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease (COPD) for one year
Source: Eur Respir J 2002; 20: Suppl. 38, 242s
Year: 2002
Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease
Source: Eur Respir J 2004; 24: 1075
Year: 2004
Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2001; 18: Suppl. 33, 146s
Year: 2001
Alveolar absorption and systemic bioactivity of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2004; 24: Suppl. 48, 13s
Year: 2004
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.
Source: Eur Respir J 2003; 21: 912
Year: 2003
Reduction of exacerbations with salmeterol/fluticasone combination 50/500mcg bd in the treatment of chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2002; 20: Suppl. 38, 241s
Year: 2002
Inhaled budesonide in the management of chronic obstructive pulmonary diseases
Source: Eur Respir J 2002; 20: Suppl. 38, 244s
Year: 2002
Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations
Source: Eur Respir J 2003; 21: 68-73
Year: 2003
Additive benefits of tiotropium in asthmatics and in patients with asthma complicated chronic obstructive pulmonary disease
Source: Eur Respir J 2007; 30: Suppl. 51, 546s
Year: 2007
Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol
Source: Eur Respir J 2004; 24: Suppl. 48, 291s
Year: 2004
Efficacy and safety of moxifloxacin in the outpatient treatment of exacerbations of chronic obstructive pulmonary disease
Source: International Congress 2018 – Pharmacological management of COPD
Year: 2018
Efficacy of budesonide/formoterol in Chinese patients with chronic obstructive pulmonary disease
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II
Year: 2008
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease
Source: Eur Respir J 2002; 19: 217-224
Year: 2002
Efficacy of lasolvan in the treatment of patients with chronic obstructive pulmonary disease
Source: Annual Congress 2009 - Drug effects in COPD
Year: 2009
A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations
Source: Eur Respir J 2013; 41: 12-17
Year: 2013
Efficacy of tiotropium bromide in patients with chronic obstructive pulmonary disease of varying severity
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II
Year: 2008
What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations?
Source: Eur Respir J 2002; 19: 928-935
Year: 2002
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept